SG11202004867WA - Glucocorticoid receptor agonist and immunoconjugates thereof - Google Patents
Glucocorticoid receptor agonist and immunoconjugates thereofInfo
- Publication number
- SG11202004867WA SG11202004867WA SG11202004867WA SG11202004867WA SG11202004867WA SG 11202004867W A SG11202004867W A SG 11202004867WA SG 11202004867W A SG11202004867W A SG 11202004867WA SG 11202004867W A SG11202004867W A SG 11202004867WA SG 11202004867W A SG11202004867W A SG 11202004867WA
- Authority
- SG
- Singapore
- Prior art keywords
- immunoconjugates
- receptor agonist
- glucocorticoid receptor
- glucocorticoid
- agonist
- Prior art date
Links
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 title 1
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 title 1
- 229940127121 immunoconjugate Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593776P | 2017-12-01 | 2017-12-01 | |
| US201762595054P | 2017-12-05 | 2017-12-05 | |
| PCT/IB2018/059482 WO2019106609A1 (en) | 2017-12-01 | 2018-11-29 | Glucocorticoid receptor agonist and immunoconjugates thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202004867WA true SG11202004867WA (en) | 2020-06-29 |
Family
ID=65010803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202004867WA SG11202004867WA (en) | 2017-12-01 | 2018-11-29 | Glucocorticoid receptor agonist and immunoconjugates thereof |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US10772970B2 (lt) |
| EP (2) | EP3884962A1 (lt) |
| JP (2) | JP6813712B2 (lt) |
| KR (1) | KR20200095477A (lt) |
| CN (1) | CN111417410B (lt) |
| AU (1) | AU2018374634A1 (lt) |
| BR (1) | BR112020010694A2 (lt) |
| CA (1) | CA3082356A1 (lt) |
| CL (2) | CL2020001452A1 (lt) |
| CO (1) | CO2020006446A2 (lt) |
| CR (1) | CR20200239A (lt) |
| CY (1) | CY1124230T1 (lt) |
| DK (1) | DK3658192T3 (lt) |
| DO (1) | DOP2020000116A (lt) |
| EC (1) | ECSP20029001A (lt) |
| ES (1) | ES2877659T3 (lt) |
| HR (1) | HRP20210917T1 (lt) |
| HU (1) | HUE054428T2 (lt) |
| IL (1) | IL274651B (lt) |
| LT (1) | LT3658192T (lt) |
| MA (1) | MA49796A (lt) |
| MX (1) | MX2020005583A (lt) |
| PE (1) | PE20201286A1 (lt) |
| PH (1) | PH12020550779A1 (lt) |
| PL (1) | PL3658192T3 (lt) |
| PT (1) | PT3658192T (lt) |
| RS (1) | RS61994B1 (lt) |
| RU (1) | RU2020117698A (lt) |
| SG (1) | SG11202004867WA (lt) |
| SI (1) | SI3658192T1 (lt) |
| TW (1) | TWI803542B (lt) |
| UA (1) | UA126595C2 (lt) |
| UY (1) | UY37991A (lt) |
| WO (1) | WO2019106609A1 (lt) |
| ZA (1) | ZA202003325B (lt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20200239A (es) * | 2017-12-01 | 2020-09-21 | Abbvie Inc | Agonista del receptor de glucocorticoides e inmunoconjugados de este |
| MX2022012991A (es) * | 2020-04-22 | 2023-01-16 | Immunext Inc | Anticuerpos anti-vista humanos y uso de estos. |
| TW202245796A (zh) | 2021-02-04 | 2022-12-01 | 大陸商上海森輝醫藥有限公司 | 糖皮質激素受體激動劑的藥物偶聯物及其在醫藥上的應用 |
| TW202304462A (zh) * | 2021-03-23 | 2023-02-01 | 美商美國禮來大藥廠 | 糖皮質素受體激動劑 |
| TW202304464A (zh) | 2021-03-23 | 2023-02-01 | 美商美國禮來大藥廠 | 新穎糖皮質素受體激動劑 |
| AR125079A1 (es) | 2021-03-23 | 2023-06-07 | Lilly Co Eli | Agonistas de receptores de glucocorticoides sustituidos con carboxi |
| JP2024523545A (ja) * | 2021-06-24 | 2024-06-28 | 江蘇先声薬業有限公司 | ステロイド系化合物、その医薬組成物及びその応用 |
| WO2023025248A1 (zh) * | 2021-08-26 | 2023-03-02 | 映恩生物制药（苏州）有限公司 | 一种甾体化合物及其缀合物 |
| CN118201943A (zh) * | 2021-09-14 | 2024-06-14 | 映恩生物制药（苏州）有限公司 | 一种抗炎症的化合物及其用途 |
| US20250152722A1 (en) * | 2022-01-29 | 2025-05-15 | Shanghai Shengdi Pharmaceutical Co., Ltd. | Drug conjugate of glucocorticoid |
| CN120239705A (zh) | 2022-07-21 | 2025-07-01 | 萤火虫生物股份有限公司 | 糖皮质激素受体激动剂和其缀合物 |
| EP4590686A1 (en) * | 2022-09-22 | 2025-07-30 | Eli Lilly and Company | Glucocorticoid receptor agonists |
| CN118236514A (zh) * | 2022-12-24 | 2024-06-25 | 津药生物科技（天津）有限公司 | 抗体-糖皮质激素偶联物及其用途 |
| TW202430226A (zh) * | 2022-12-28 | 2024-08-01 | 大陸商上海盛迪醫藥有限公司 | 抗cd40抗體藥物偶聯物、其製備方法及其醫藥用途 |
| WO2024149093A1 (zh) * | 2023-01-10 | 2024-07-18 | 四川科伦博泰生物医药股份有限公司 | 糖皮质激素受体激动剂及其偶联物 |
| WO2024153162A1 (en) * | 2023-01-18 | 2024-07-25 | Shanghai Micurx Pharmaceutical Co., Ltd. | Peptide-drug conjugates for targeted therapy of renal diseases |
| WO2025026216A1 (zh) * | 2023-07-28 | 2025-02-06 | 江苏恒瑞医药股份有限公司 | 一种含有糖皮质激素的抗体药物偶联物的药物组合物 |
Family Cites Families (134)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3126375A (en) | 1964-03-24 | Chioacyl | ||
| GB933868A (en) | 1958-12-08 | 1963-08-14 | American Cyanamid Co | Process for fluorinating steroids |
| IT1057859B (it) | 1972-04-28 | 1982-03-30 | Sigma Tao Ind Farmaceutiche Sp | Perivato del triamoinolone |
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE3889853D1 (de) | 1987-11-05 | 1994-07-07 | Hybritech Inc | Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik. |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5010176A (en) | 1988-11-10 | 1991-04-23 | Eli Lilly And Company | Antibody-drug conjugates |
| GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
| US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| ATE172739T1 (de) | 1993-04-02 | 1998-11-15 | Byk Gulden Lomberg Chem Fab | Neue prednisolonderivate |
| WO1994025478A1 (en) | 1993-04-29 | 1994-11-10 | Instytut Farmaceutyczny | 16α,17α-ACETAL GLUCOCORTICOSTEROIDAL DERIVATIVES |
| EP0749438B1 (de) | 1994-03-09 | 2000-12-13 | Byk Gulden Lomberg Chemische Fabrik GmbH | Neue silylverbindungen und ihre verwendung |
| JP2749778B2 (ja) | 1994-09-05 | 1998-05-13 | 日清食品株式会社 | トリアムシノロン誘導体 |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| US5792758A (en) | 1995-12-08 | 1998-08-11 | G. D. Searle & Co. | Steroid nitrite ester derivatives useful as anti-inflammatory drugs |
| IL125697A (en) | 1996-02-09 | 2005-03-20 | Abbott Lab Bermuda Ltd | HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha |
| US5824669A (en) | 1996-03-22 | 1998-10-20 | Nitromed, Inc. | Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders |
| DE19635498A1 (de) | 1996-09-03 | 1998-03-26 | Byk Gulden Lomberg Chem Fab | Verfahren zur Epimerenanreicherung |
| AU3703900A (en) | 1999-02-24 | 2000-09-14 | Nitromed, Inc. | Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders |
| US8383081B2 (en) | 1999-05-10 | 2013-02-26 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
| GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| SK287545B6 (sk) | 2000-11-10 | 2011-01-04 | Nycomed Gmbh | Spôsob prípravy 16,17-[(cyklohexylmetylén)bis(oxy)]-11,21- dihydroxy-pregna-1,4-dién-3,20-diónu a podobných zlúčenín |
| DE10055820C1 (de) | 2000-11-10 | 2002-07-25 | Byk Gulden Lomberg Chem Fab | Verfahren zur Herstellung eines Glucocorticoids |
| CA2868614A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| CN1671416B (zh) | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| EP2279753B1 (en) | 2001-10-10 | 2015-09-16 | Novo Nordisk A/S | Remodeling and glycoconjugation of peptides |
| JP4304073B2 (ja) | 2001-11-12 | 2009-07-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 改変された抗ＴＮＦα抗体 |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| US20040157810A1 (en) | 2002-08-23 | 2004-08-12 | Teicher Martin H. | Corticosteroid conjugates and uses thereof |
| MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| US8232304B2 (en) | 2002-10-24 | 2012-07-31 | G & R Pharmaceuticals, Llc | Antifungal formulations |
| US7432275B2 (en) | 2002-12-13 | 2008-10-07 | Neurogen Corporation | Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators |
| EP1589996A4 (en) | 2003-01-30 | 2009-01-21 | Medimmune Inc | ANTI-INTEGRIN ALPHA BETA 3 ANTIBODY FORMULATIONS AND ITS USES |
| MY143936A (en) | 2003-03-27 | 2011-07-29 | Nycomed Gmbh | Process for preparing crystalline ciclesonide with defined particle size |
| WO2005044759A2 (en) | 2003-08-14 | 2005-05-19 | Sun Pharmaceutical Industries Limited | Acetalization process for preparation of steroid compounds |
| WO2005025578A1 (en) | 2003-09-16 | 2005-03-24 | Altana Pharma Ag | Use of ciclesonide for the treatment of respiratory diseases |
| WO2005028495A1 (en) | 2003-09-24 | 2005-03-31 | Glaxo Group Limited | Anti-inflammatory glucocorticoids |
| WO2005041865A2 (en) | 2003-10-21 | 2005-05-12 | Igf Oncology, Llc | Compounds and method for treating cancer |
| AU2004289428B2 (en) | 2003-11-13 | 2010-06-03 | F. Hoffmann-La Roche Ag | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones |
| PT1697370E (pt) | 2003-12-19 | 2007-05-31 | Bristol Myers Squibb Co | Heterociclos azabicíclicos como moduladores do receptor de canabinóides |
| WO2005063777A1 (en) | 2003-12-23 | 2005-07-14 | Corus Pharma | Benzylphosphate and substituted benzylphosphate prodrugs for the treatment of pulmonary inflammation |
| RU2006127432A (ru) | 2003-12-31 | 2008-02-10 | Сайдекс, Инк. (Us) | Ингаляционная композиция, содержащая сульфоалкиловый эфир циклодекстрина и кортикостероид, полученная из единичной дозы суспензии |
| GB0402797D0 (en) | 2004-02-09 | 2004-03-10 | Novartis Ag | Organic compounds |
| US7837980B2 (en) | 2004-03-02 | 2010-11-23 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
| US20080187954A1 (en) | 2004-03-10 | 2008-08-07 | Lonza Ltd. | Method For Producing Antibodies |
| KR100863776B1 (ko) | 2004-07-15 | 2008-10-16 | 젠코어 인코포레이티드 | 최적화된 Ｆｃ 변이체 |
| CA2581208A1 (en) | 2004-08-30 | 2006-03-09 | Lonza Biologics Plc. | Affinity- plus ion exchange- chromatography for purifying antibodies |
| PT2990422T (pt) | 2004-09-03 | 2018-10-18 | Genentech Inc | Antagonistas humanizados anti-beta7 e suas utilizações |
| CA2579007A1 (en) | 2004-09-10 | 2006-03-16 | Altana Pharma Ag | Ciclesonide and syk inhibitor combination and methods of use thereof |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2006065533A2 (en) | 2004-11-29 | 2006-06-22 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| WO2006097458A1 (en) | 2005-03-15 | 2006-09-21 | Nycomed Gmbh | Novel combination |
| WO2006110593A2 (en) | 2005-04-07 | 2006-10-19 | Macrogenics, Inc. | Biological targets for the diagnosis, treatment and prevention of cancer |
| EP1712220A1 (en) | 2005-04-15 | 2006-10-18 | PARI GmbH Spezialisten für effektive Inhalation | Pharmaceutical aerosol composition |
| WO2006135479A2 (en) | 2005-05-10 | 2006-12-21 | Angiotech International Ag | Anti-scarring agents, therapeutic compositions, and use thereof |
| US20100209508A1 (en) | 2005-06-14 | 2010-08-19 | Corus Pharma, Inc. | Substituted Phenylphosphates as Mutual Prodrugs of Steroids and ß-Agonists for the Treatment of Title Pulmonary Inflammation and Bronchoconstriction |
| CN103127523A (zh) | 2005-06-20 | 2013-06-05 | Psma开发有限公司 | Psma抗体-药物缀合物 |
| WO2007054974A2 (en) | 2005-09-28 | 2007-05-18 | Arch Pharmalab Limited | A green chemistry process for the preparation of pregnadiene esters |
| CA2648582C (en) | 2006-04-07 | 2016-12-06 | Nektar Therapeutics Al, Corporation | Conjugates of an anti-tnf-alpha antibody |
| WO2008015696A2 (en) | 2006-05-23 | 2008-02-07 | Cadila Healthcare Limited | Process for preparing ciclesonide |
| TWI523864B (zh) | 2006-05-30 | 2016-03-01 | 建南德克公司 | 抗體及免疫接合物及其用途 |
| AU2007298770B2 (en) | 2006-09-19 | 2013-01-31 | Cipla Limited | Processes for the preparation of ciclesonide and its crystal form |
| WO2008052350A1 (en) | 2006-11-03 | 2008-05-08 | Qlt Inc. | Photodynamic therapy for the treatment of hidradenitis suppurativa |
| NO331891B1 (no) | 2007-03-20 | 2012-04-30 | Clavis Pharma Asa | Kjemiske forbindelser, et farmasoytisk preparat inneholdende slike forbindelser, samt anvendelse derav for behandling av kreft, inflammasjon og KOLS |
| UA100120C2 (en) | 2007-04-03 | 2012-11-26 | Анадис Фармасьютикалз, Инк. | 5,6-dihydro-1h-pyridin-2-one compounds |
| PT2173169E (pt) | 2007-06-28 | 2014-09-03 | Cydex Pharmaceuticals Inc | Entrega nasal de soluções de corticosteróide aquosas |
| BRPI0820447A2 (pt) | 2007-11-30 | 2015-05-26 | Pfizer Ltd | Agonistas do receptor de glicocorticóides |
| JP2011507878A (ja) | 2007-12-21 | 2011-03-10 | シェーリング コーポレイション | Ｃ２０−ｃ２１置換グルココルチコイド受容体アゴニスト |
| WO2009085880A2 (en) | 2007-12-21 | 2009-07-09 | Schering Corporation | C-21 thioethers as glucocorticoid receptor agonists |
| HUE032025T2 (en) | 2008-01-31 | 2017-08-28 | Inserm - Inst Nat De La Sante Et De La Rech Medicale | Antibodies to human CD39 and their use to inhibit regulatory T cell activity |
| RU2010133722A (ru) | 2008-02-27 | 2012-04-10 | Астразенека Аб (Se) | 16-альфа, 17-альфа-ацетальглюкокортикостероидные производные и их применение |
| JP2011513469A (ja) | 2008-03-13 | 2011-04-28 | ファルマビオス ソシエタ ペル アチオニ | プレグナン誘導体の製造法 |
| TW201010707A (en) | 2008-06-10 | 2010-03-16 | Gilead Sciences Inc | Corticosteroid linked beta-agonist compounds for use in therapy |
| MX2010013833A (es) | 2008-06-16 | 2011-02-15 | Immunogen Inc | Nuevos efectos sinergisticos. |
| KR101273765B1 (ko) | 2008-06-24 | 2013-06-12 | 아이알엠 엘엘씨 | Ｇ 단백질-커플링된 수용체를 조정하는 화합물 및 방법 |
| WO2010054158A2 (en) | 2008-11-07 | 2010-05-14 | Auspex Pharmaceuticals, Inc. | Steroid modulators of glucocorticoid receptor |
| BRPI0922807A2 (pt) | 2008-12-04 | 2015-12-22 | Abbott Lab | imonuglobulinas de domínio variável duplo e usos dos mesmos |
| LT2786762T (lt) | 2008-12-19 | 2019-06-10 | Macrogenics, Inc. | Kovalentiniai diakūnai ir jų panaudojimas |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| AU2010221972B2 (en) | 2009-03-09 | 2012-07-05 | Mikasa Seiyaku Co., Ltd. | Steroid compound |
| WO2010126953A1 (en) | 2009-04-29 | 2010-11-04 | Gilead Sciences, Inc. | Corticosteroid linked beta-agonist compounds for use in therapy |
| WO2010132743A1 (en) | 2009-05-15 | 2010-11-18 | Gilead Sciences, Inc. | Corticosteroid beta-agonist compounds for use in therapy |
| CA2760284A1 (en) | 2009-05-29 | 2010-12-02 | Pfizer Limited | Novel glucocorticoid receptor agonists |
| GB0917044D0 (en) | 2009-09-29 | 2009-11-18 | Cytoguide As | Agents, uses and methods |
| EP3778917A3 (en) | 2009-12-04 | 2021-06-09 | F. Hoffmann-La Roche AG | Multispecific antibodies, antibody analogs, compositions, and methods |
| WO2011072124A1 (en) | 2009-12-09 | 2011-06-16 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
| WO2011081937A1 (en) | 2009-12-15 | 2011-07-07 | Gilead Sciences, Inc. | Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy |
| CN102167741B (zh) | 2010-02-25 | 2014-05-14 | 上海百迈博制药有限公司 | 一种全人源抗TNF-α单克隆抗体、其制备方法及用途 |
| BR112012025568A2 (pt) | 2010-04-07 | 2017-03-28 | Abbvie Inc | proteínas de ligação ao tnf-<244>. |
| TWI586806B (zh) | 2010-04-23 | 2017-06-11 | 建南德克公司 | 異多聚體蛋白質之製造 |
| EP3566719A1 (en) | 2010-05-18 | 2019-11-13 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
| PT2575884T (pt) | 2010-06-03 | 2018-10-31 | Abbvie Biotechnology Ltd | Utilizações e composições para o tratamento de hidradenite supurativa (hs) |
| KR20130043168A (ko) | 2010-06-24 | 2013-04-29 | 아비에 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| WO2012040228A2 (en) | 2010-09-22 | 2012-03-29 | Map Pharmaceuticals, Inc. | Aerosol composition for administering drugs |
| AR084210A1 (es) | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
| WO2012082947A1 (en) | 2010-12-16 | 2012-06-21 | Irm Llc | Compounds and compositions as tgr5 agonists |
| US9848048B2 (en) | 2010-12-29 | 2017-12-19 | Nokia Solutions And Networks Oy | Method and apparatus for transmitting an identity |
| WO2012131053A1 (en) | 2011-03-30 | 2012-10-04 | Ablynx Nv | Methods of treating immune disorders with single domain antibodies against tnf-alpha |
| KR20140084253A (ko) | 2011-10-24 | 2014-07-04 | 애브비 인코포레이티드 | Ｔｎｆ에 대한 면역결합제 |
| CA2853114A1 (en) | 2011-10-24 | 2013-05-02 | Abbvie Inc. | Bispecific immunobinders directed against tnf and il-17 |
| US20130115269A1 (en) | 2011-11-04 | 2013-05-09 | Henry John Smith | Anti-tumor necrosis factor alpha (TNF-a) antibody used as a targeting agent to treat arthritis and other diseases |
| US9573996B2 (en) | 2011-12-16 | 2017-02-21 | Synthon Biopharmaceuticals B.V. | Monoclonal antibodies to human proinflammatory cytokines and methods for treating inflammatory diseases |
| US9109005B2 (en) | 2012-02-23 | 2015-08-18 | Boehringer Ingelheim International Gmbh | Method for manufacturing of ciclesonide |
| EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
| EP2647627A1 (en) | 2012-04-02 | 2013-10-09 | Almirall, S.A. | Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one. |
| CN103421075B (zh) | 2012-05-16 | 2017-07-28 | 上海特化医药科技有限公司 | 孕烷衍生物16,17‑缩醛(酮)的制备方法 |
| EP2855745A4 (en) | 2012-06-01 | 2016-01-20 | Momenta Pharmaceuticals Inc | METHODS RELATING TO ADALIMUM AB |
| CN104854133B (zh) | 2012-10-12 | 2018-10-30 | 新加坡科技研究局 | 用于制备重组抗体治疗剂的最佳重链和轻链信号肽 |
| WO2014080251A1 (en) | 2012-11-24 | 2014-05-30 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
| ES2819573T3 (es) | 2012-12-13 | 2021-04-16 | Immunomedics Inc | Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A |
| ES2909039T3 (es) | 2012-12-21 | 2022-05-05 | Boehringer Ingelheim Vetmedica Gmbh | Formulación farmacéutica que comprende ciclesonida |
| HK1218920A1 (zh) | 2013-03-15 | 2017-03-17 | Abbvie Inc. | 改善的tnf結合蛋白 |
| CA2920192A1 (en) | 2013-09-27 | 2015-04-02 | Immunomedics, Inc. | Anti-trop-2 antibody-drug conjugates and uses thereof |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| DK3122757T3 (da) | 2014-02-28 | 2023-10-09 | Hangzhou Dac Biotech Co Ltd | Ladede linkere og anvendelse deraf til konjugering |
| US10550190B2 (en) | 2014-04-04 | 2020-02-04 | Merck Sharp & Dohme Corp. | Phosphate based linkers for intracellular delivery of drug conjugates |
| EP3160499A4 (en) | 2014-06-30 | 2018-03-14 | Immunomedics, Inc. | Antibodies reactive with an epitope located in the n-terminal region of muc5ac comprising cysteine-rich subdomain 2 (cys2) |
| KR20170055544A (ko) | 2014-09-19 | 2017-05-19 | 옥슬러 리미티드 | 안과용 약물 조성물 |
| US10233210B2 (en) | 2015-01-30 | 2019-03-19 | Coral Drugs Pvt. Ltd. | Process for preparation of glucocorticoid steroids |
| JP2016190798A (ja) | 2015-03-31 | 2016-11-10 | 三笠製薬株式会社 | アレルギー性鼻炎治療用局所点鼻薬 |
| EP3307749A4 (en) | 2015-06-15 | 2019-06-19 | Hangzhou Dac Biotech Co., Ltd | HYDROPHILIC LINKER FOR CONJUGATION |
| CN107921144B (zh) | 2015-06-20 | 2023-11-28 | 杭州多禧生物科技有限公司 | 澳瑞他汀类似物及其与细胞结合分子的共轭偶联物 |
| CN108289964B (zh) | 2015-08-10 | 2022-08-12 | 杭州多禧生物科技有限公司 | 新型连接体及其用于药物和生物分子的特异性偶联 |
| JP2017066075A (ja) | 2015-09-30 | 2017-04-06 | 三笠製薬株式会社 | リウマチ治療薬 |
| TWI728118B (zh) * | 2016-06-02 | 2021-05-21 | 美商艾伯維有限公司 | 糖皮質素受體促效劑及其免疫結合物 |
| JP6767796B2 (ja) | 2016-07-08 | 2020-10-14 | 株式会社日立情報通信エンジニアリング | 通話管理システム及びその音声認識制御方法 |
| US10711032B2 (en) | 2016-11-08 | 2020-07-14 | Regeneron Pharmaceuticals, Inc. | Steroids and protein-conjugates thereof |
| CR20200239A (es) * | 2017-12-01 | 2020-09-21 | Abbvie Inc | Agonista del receptor de glucocorticoides e inmunoconjugados de este |
-
2018
- 2018-11-29 CR CR20200239A patent/CR20200239A/es unknown
- 2018-11-29 PH PH1/2020/550779A patent/PH12020550779A1/en unknown
- 2018-11-29 BR BR112020010694-1A patent/BR112020010694A2/pt unknown
- 2018-11-29 EP EP21162680.9A patent/EP3884962A1/en active Pending
- 2018-11-29 PE PE2020000608A patent/PE20201286A1/es unknown
- 2018-11-29 HU HUE18833113A patent/HUE054428T2/hu unknown
- 2018-11-29 DK DK18833113.6T patent/DK3658192T3/da active
- 2018-11-29 WO PCT/IB2018/059482 patent/WO2019106609A1/en not_active Application Discontinuation
- 2018-11-29 HR HRP20210917TT patent/HRP20210917T1/hr unknown
- 2018-11-29 AU AU2018374634A patent/AU2018374634A1/en active Pending
- 2018-11-29 PL PL18833113T patent/PL3658192T3/pl unknown
- 2018-11-29 TW TW107142830A patent/TWI803542B/zh not_active IP Right Cessation
- 2018-11-29 KR KR1020207015633A patent/KR20200095477A/ko active Pending
- 2018-11-29 EP EP18833113.6A patent/EP3658192B1/en active Active
- 2018-11-29 ES ES18833113T patent/ES2877659T3/es active Active
- 2018-11-29 PT PT188331136T patent/PT3658192T/pt unknown
- 2018-11-29 CA CA3082356A patent/CA3082356A1/en active Pending
- 2018-11-29 SG SG11202004867WA patent/SG11202004867WA/en unknown
- 2018-11-29 MX MX2020005583A patent/MX2020005583A/es unknown
- 2018-11-29 MA MA049796A patent/MA49796A/fr unknown
- 2018-11-29 JP JP2020512845A patent/JP6813712B2/ja active Active
- 2018-11-29 CN CN201880077432.9A patent/CN111417410B/zh active Active
- 2018-11-29 RU RU2020117698A patent/RU2020117698A/ru unknown
- 2018-11-29 RS RS20210761A patent/RS61994B1/sr unknown
- 2018-11-29 US US16/204,825 patent/US10772970B2/en active Active
- 2018-11-29 LT LTEP18833113.6T patent/LT3658192T/lt unknown
- 2018-11-29 SI SI201830305T patent/SI3658192T1/sl unknown
- 2018-11-29 UA UAA202003245A patent/UA126595C2/uk unknown
- 2018-12-03 UY UY0001037991A patent/UY37991A/es not_active Application Discontinuation
-
2020
- 2020-05-13 IL IL274651A patent/IL274651B/en active IP Right Grant
- 2020-05-27 CO CONC2020/0006446A patent/CO2020006446A2/es unknown
- 2020-05-29 CL CL2020001452A patent/CL2020001452A1/es unknown
- 2020-05-29 EC ECSENADI202029001A patent/ECSP20029001A/es unknown
- 2020-06-03 ZA ZA2020/03325A patent/ZA202003325B/en unknown
- 2020-06-15 DO DO2020000116A patent/DOP2020000116A/es unknown
- 2020-07-31 US US16/945,069 patent/US20210015938A1/en not_active Abandoned
- 2020-12-17 JP JP2020209056A patent/JP2021054845A/ja active Pending
-
2021
- 2021-04-26 CL CL2021001075A patent/CL2021001075A1/es unknown
- 2021-06-18 CY CY20211100547T patent/CY1124230T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201808623B (en) | Glucocorticoid receptor agonist and immunoconjugates thereof | |
| ZA202003325B (en) | Glucocorticoid receptor agonist and immunoconjugates thereof | |
| IL269065A (en) | Paranoid X receptor agonists and uses thereof | |
| IL269068A (en) | Paranoid X receptor agonists and uses thereof | |
| IL276340A (en) | PD-1 agonistic antibodies and their uses | |
| ZA201801750B (en) | Farnesoid x receptor agonists and uses thereof | |
| IL260789B (en) | Selective estrogen receptor antagonists and their uses | |
| SG11202103609YA (en) | T-cell receptors and uses thereof | |
| SG11202102651SA (en) | Farnesoid x receptor agonists and uses thereof | |
| IL281471A (en) | Farnesoid x receptor agonists and uses thereof | |
| IL281474A (en) | Farnesoid x receptor agonists and uses thereof | |
| ZA201906954B (en) | Btla agonist antibodies and uses thereof | |
| IL274751A (en) | ILDR2 antagonists and combinations thereof | |
| EP3445769A4 (en) | THYROID HORMONE RECEPTOR AGONIST AND ITS USE | |
| IL266721A (en) | Anti-gp73 antibodies and immunoconjugates | |
| GB201520191D0 (en) | T-cell receptor and uses thereof | |
| ZA201905441B (en) | Antigen receptors and uses thereof | |
| GB2585607B (en) | Chimeric antigen receptor and application thereof | |
| EP3135669A4 (en) | Oxazolidine-based compound and selective androgen receptor agonist comprising same | |
| HK40005327A (en) | Thyroid hormone receptor agonist and use thereof | |
| HK40019860B (en) | Farnesoid x receptor agonists and uses thereof | |
| HK40019851B (en) | Farnesoid x receptor agonists and uses thereof | |
| GB201700981D0 (en) | Composition and device |